Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $82.38 Analyst target: $139.06 Upside: 68.80%
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. The company is headquartered in New York, New York.
See the full interactive analysis & chart →Informational only — not investment advice.